Effect of Soliqua 100/33 on Time in Range from Continuous Glucose Monitoring in Insulin-naive Patients with Very Uncontrolled Type 2 Diabetes Mellitus

Trial Identifier: LPS16990
Sponsor: Sanofi
Start Date: January 2022
Primary Completion Date: March 2023
Study Completion Date: April 2023
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, California Canyon Country, California, United States, 91351-4138
United States, California Huntington Park, California, United States, 90255-2959
United States, California Lomita, California, United States, 90717-2101
United States, California Los Angeles, California, United States, 90017-5649
United States, California Tustin, California, United States, 92780
United States, California West Hills, California, United States, 91304-3837
United States, Florida Miami, Florida, United States, 33179-2537
United States, Florida Miami, Florida, United States, 33165-7043
United States, Nevada Las Vegas, Nevada, United States, 89128-0463
United States, New Jersey Berlin, New Jersey, United States, 08009
United States, New York New Windsor, New York, United States, 12553-7754
United States, Ohio Columbus, Ohio, United States, 43201-3209
United States, Tennessee Memphis, Tennessee, United States, 38163
United States, Texas Dallas, Texas, United States, 75390
United States, Texas San Antonio, Texas, United States, 78229-3539
United States, Texas Schertz, Texas, United States, 78154
United States, Texas Shavano Park, Texas, United States, 78231-1281